<DOC>
	<DOC>NCT00793156</DOC>
	<brief_summary>Primary objective of this multicenter, double-blind, placebo controlled, randomized withdrawal study are to determine the effectiveness and safety of orally administered AC-820 in doses of 2.5 µg and 5.0 µg daily in patients with moderate to severe itching associated with end-stage renal disease and hemodialysis, and perform a population PK analysis.</brief_summary>
	<brief_title>A Randomized-Withdrawal Phase 3 Study Evaluating the Safety and Efficacy of Oral Nalfurafine HCl (AC-820)in Subjects on Hemodialysis With Uremic Pruritus (Renal Itch)</brief_title>
	<detailed_description />
	<mesh_term>Pruritus</mesh_term>
	<criteria>18 yrs old or older moderate to severe pruritus end stage renal disease 3x weekly hemodialysis pruritus not due to renal disease abnormal liver function CaP &gt; 80 mg/dl or HgB &lt;8.5 g/dl or PTH &gt; pg/mL Within four months spKt/V &lt; 1.05</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>uremic pruritus</keyword>
</DOC>